XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
Cell Host & Microbe · 2024-03 · 32 (3) · 315-321.e3
DOI: 10.1016/j.chom.2024.01.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Host & Microbe, 2024-03. Verfasst von Qian Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA. Hauptthemen laut MEDLINE: mRNA Vaccines, Antibodies, Neutralizing. Die Arbeit wurde bisher 178-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, Janssen Pharmaceutica.
Abstract (Originalsprache)
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report that administration of an updated monovalent mRNA vaccine booster (XBB.1.5 MV) to previously uninfected individuals boosted serum virus-neutralizing antibodies significantly against not only XBB.1.5 (27.0-fold increase) and EG.5.1 (27.6-fold increase) but also key emerging viruses such as HV.1, HK.3, JD.1.1, and JN.1 (13.3- to 27.4-fold increase). Individuals previously infected by an Omicron subvariant had the highest overall serum neutralizing titers (ID50 1,504-22,978) against all viral variants tested. While immunological imprinting was still evident with the updated vaccines, it was not nearly as severe as observed with the previously authorized bivalent BA.5 vaccine. Our findings strongly support the official recommendation to widely apply the updated COVID-19 vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
- Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College o…
- Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians an…
- Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Epidemiology, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: gordonal@umich.edu.
Förderung
- NIAID NIH HHS
- National Institutes of Health
- Janssen Pharmaceutica
- Bill & Melinda Gates Foundation
Zitieren
APA
Wang, Q., Guo, Y., Bowen, A., Mellis, I. A., Valdez, R., Gherasim, C., Gordon, A., Liu, L., & Ho, D. D. (2024). XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host & Microbe, 32(3), 315-321.e3. https://doi.org/10.1016/j.chom.2024.01.014
Vancouver
Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host & Microbe. 2024;32(3):315-321.e3. doi:10.1016/j.chom.2024.01.014
BibTeX
@article{Wang2024,
author = {Wang, Qian and Guo, Yicheng and Bowen, Anthony and Mellis, Ian A and Valdez, Riccardo and Gherasim, Carmen and Gordon, Aubree and Liu, Lihong and Ho, David D},
title = {XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1},
journal = {Cell Host & Microbe},
year = {2024},
volume = {32},
number = {3},
pages = {315--321.e3},
doi = {10.1016/j.chom.2024.01.014}
}
EUVIMED